NCT00802542已完成不适用
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Decrease in blood pressure
研究概览
简要总结
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided
- •Signed and dated Patient Informed Consent (ICF)
排除标准
- •Hypersensitivity to the active substance or to any of the excipients of Atacand.
结局指标
主要结局
Decrease in blood pressure
时间窗: once after 4 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic PainPainNCT00799656Sanofi62
Unknown
2 期
Phase II AK Study in Organ Transplant PatientsActinic KeratosesCarcinoma, Squamous CellOrgan Transplant RecipientsNCT00829192Clinuvel Pharmaceuticals Limited200
已完成
2 期
A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve CalcificationAortic Valve StenosisNCT02481258Mayo Clinic35
撤回
2 期
A Multi-Dose Study With a Treatment for Open-Angle GlaucomaOpen-Angle GlaucomaNCT00705770Alcon Research
已完成
2 期
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)Minimal Change DiseaseFocal Segmental GlomerulosclerosisNephrotic SyndromeNCT02592798Bristol-Myers Squibb36